" /> Tixagevimab - CISMeF





Preferred Label : Tixagevimab;

NCIt definition : A neutralizing human monoclonal antibody isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration, tixagevimab specifically targets and binds to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.;

UNII : F0LZ415Z3B;

CAS number : 2420564-02-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2420564-02-7 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Molecule name : AZD 8895; COV2-2196; AZD-8895;

NCI Metathesaurus CUI : CL1642820;

Details


You can consult :


Nous contacter.
21/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.